Access keys

Skip to content Accessibility Home News, events and publications Site map Search Privacy policy Help Contact us Terms of use

Hens that lay human proteins in eggs offer future therapy hope

Copyright free (Pexels/Creative Commons CC0)
News from: The Roslin Institute

Chickens that are genetically modified to produce human proteins in their eggs can offer a cost-effective method of producing certain types of drugs, research suggests.

The study - which has initially focused on producing high quality proteins for use in scientific research - found the drugs work at least as well as the same proteins produced using existing methods.

High quantities of the proteins can be recovered from each egg using a simple purification system and there are no adverse effects on the chickens themselves, which lay eggs as normal.

Researchers say the findings provide sound evidence for using chickens as a cheap method of producing high quality drugs for use in research studies and, potentially one day, in patients.

Eggs are already used for growing viruses that are used as vaccines, such as the flu jab. This new approach is different because the therapeutic proteins are encoded in the chicken’s DNA and produced as part of the egg white.

The team have initially focused on two proteins that are essential to the immune system and have therapeutic potential - a human protein called IFNalpha2a, which has powerful antiviral and anti-cancer effects, and the human and pig versions of a protein called macrophage-CSF, which is being developed as a therapy that stimulates damaged tissues to repair themselves.

Just three eggs were enough to produce a clinically relevant dose of the drug. As chickens can lay up to 300 eggs per year, researchers say their approach could be more cost-effective than other production methods for some important drugs.

Researchers say they haven’t produced medicines for use in patients yet but the study offers proof-of-principle that the system is feasible and could easily be adapted to produce other therapeutic proteins.

Protein-based drugs, which include antibody therapies such as Avastin and Herceptin, are widely used for treating cancer and other diseases.

For some of these proteins, the only way to produce them with sufficient quality involves mammalian cell culture techniques, which are expensive and have low yields. Other methods require complex purification systems and additional processing techniques, which raise costs.

Scientists have previously shown that genetically modified goats, rabbits and chickens can be used to produce protein therapies in their milk or eggs. The researchers say their new approach is more efficient, produces better yields and is more cost-effective than these previous attempts.

The study was carried out at The University of Edinburgh’s The Roslin Institute and Roslin Technologies, a company set up to commercialise research at The Roslin Institute.

The research is published in BMC Biotechnology. The Roslin Institute receives strategic funding from the Biotechnology and Biological Sciences Research Council.

“These recent findings provide a promising proof of concept for future drug discovery and potential for developing more economical protein-based drugs,” said Dr Ceri Lyn-Adams, Head of Science Strategy, Bioscience for Health with BBSRC.

Professor Helen Sang, of The University of Edinburgh’s The Roslin Institute, said: “We are not yet producing medicines for people, but this study shows that chickens are commercially viable for producing proteins suitable for drug discovery studies and other applications in biotechnology.”

Dr Lissa Herron, Head of the Avian Biopharming Business Unit at Roslin Technologies, said: “We are excited to develop this technology to its full potential, not just for human therapeutics in the future but also in the fields of research and animal health.”

ENDS

About BBSRC

The Biotechnology and Biological Sciences Research Council (BBSRC) is part of UK Research and Innovation, a non-departmental public body funded by a grant-in-aid from the UK government.

BBSRC invests in world-class bioscience research and training on behalf of the UK public. Our aim is to further scientific knowledge, to promote economic growth, wealth and job creation and to improve quality of life in the UK and beyond.

Funded by government, BBSRC invested £498 million in world-class bioscience in 2017-18. We support research and training in universities and strategically funded institutes. BBSRC research and the people we fund are helping society to meet major challenges, including food security, green energy and healthier, longer lives. Our investments underpin important UK economic sectors, such as farming, food, industrial biotechnology and pharmaceuticals.

More information about UK Research and Innovation.
More information about BBSRC, our science and our impact.
More information about BBSRC strategically funded institutes.

External contact

Jen Middleton, Press and PR Office, The University of Edinburgh


0131 650 6514


Tags: press release health The Roslin Institute pharmaceuticals human health genetics